ARTVHealthcareMicro-Cap
Artiva Biotherapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Artiva Biotherapeutics, Inc. (ARTV), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are ARTV insiders buying or selling?
Artiva Biotherapeutics, Inc. insiders reported 12 open-market buys ($270.7M) and 9 sells ($741.0K) across 21 Form 4 filings — a net buying position of $269.9M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jul 20, 2026)
Total Form 4 filings
21
SEC EDGAR
Insider filers
10
Insider buys (12)
$270.7M
Insider sells (9)
$741.0K
Insider sentiment
Net buyingNet insider flow of $269.9M in net buying. 7 insider buys in the last 90 days.
Recent ARTV insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 20, 2026 | Peter Kolchinsky | Director, 10% Owner | Purchase | 160.4K | $8.93 | $1.4M |
| Jul 14, 2026 | Peter Kolchinsky | Director, 10% Owner | Purchase | 21.7K | $8.96 | $194.0K |
| Jun 29, 2026 | Peter Kolchinsky | Director, 10% Owner | Purchase | 32.9K | $8.89 | $292.1K |
| Jun 16, 2026 | Peter Kolchinsky | Director, 10% Owner | Purchase | 531.3K | $8.66 | $4.6M |
| Jun 11, 2026 | Peter Kolchinsky | Director, 10% Owner | Purchase | 1.0M | $7.44 | $7.7M |
| May 28, 2026 | GC Corp. | 10% Owner | Purchase | 1.4M | $11.52 | $16.5M |
| May 20, 2026 | Heather Raymon | SVP, Research and Development | Sale | 3.1K | $9.01 | $27.9K |
| May 20, 2026 | Christopher Horan | Chief Tech Operations Officer | Sale | 7.0K | $9.01 | $63.1K |
| May 20, 2026 | Jennifer Bush | COO, CLO, Compliance Officer | Sale | 8.8K | $9.01 | $79.2K |
| May 20, 2026 | Subhashis Banerjee | Chief Medical Officer | Sale | 7.0K | $9.01 | $63.4K |
| May 20, 2026 | Fred Aslan | Chief Executive Officer | Sale | 27.1K | $9.01 | $244.3K |
| May 13, 2026 | Peter Kolchinsky | Director, 10% Owner | Purchase | 6.5M | $11.52 | $75.0M |
| Dec 16, 2025 | Fred Aslan | President and CEO | Sale | 3.2K | $6.00 | $19.1K |
| Nov 18, 2025 | Fred Aslan | President and CEO | Sale | 6.4K | $3.38 | $21.5K |
| Oct 18, 2025 | Fred Aslan | President and CEO | Sale | 25.5K | $6.00 | $153.0K |
| Aug 19, 2025 | Fred Aslan | President and CEO | Sale | 25.5K | $2.73 | $69.6K |
| Jul 24, 2024 | Peter Kolchinsky | Director, 10% Owner | Purchase | 8.3M | $12.00 | $100.0M |
| Jul 24, 2024 | Kush Parmar | 10% Owner | Purchase | 833.3K | $12.00 | $10.0M |
| Jul 23, 2024 | Robert J Adelman | 10% Owner | Purchase | 416.7K | $12.00 | $5.0M |
| Jul 23, 2024 | GC Corp. | 10% Owner | Purchase | 2.1M | $12.00 | $25.0M |
| Jul 23, 2024 | Yong-Jun Huh | Director | Purchase | 2.1M | $12.00 | $25.0M |
Showing the 21 most recent of 21 Form 4 filings for Artiva Biotherapeutics, Inc..
Most active ARTV insiders
- Peter Kolchinsky7 filings
- Fred Aslan5 filings
- GC Corp.2 filings
- Kush Parmar1 filing
- Christopher Horan1 filing
Ask anything about ARTV insider activity
Use Trabud's AI agent to query Artiva Biotherapeutics, Inc.'s Form 4 history in plain English — "Show me ARTV CEO purchases this year" or compare it against any other ticker.
Open the AI agentARTV insider trading FAQ
Are Artiva Biotherapeutics, Inc. insiders buying or selling?
Across 21 SEC Form 4 filings, Artiva Biotherapeutics, Inc. (ARTV) insiders reported 12 open-market purchases totaling $270.7M and 9 sales totaling $741.0K. That is a net buying position of $269.9M.
How many insiders trade ARTV stock?
10 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Artiva Biotherapeutics, Inc.. The most recent filing was accepted on Jul 20, 2026.
Where does Trabud get ARTV insider trading data?
All ARTV insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.